<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01919489</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00068128</org_study_id>
    <secondary_id>(UTN) U1111-1139-2991</secondary_id>
    <nct_id>NCT01919489</nct_id>
  </id_info>
  <brief_title>Liraglutide Hospital Discharge Trial</brief_title>
  <official_title>A Randomized Controlled Trial Comparing the Safety and Efficacy of Liraglutide Versus Glargine Insulin for the Management of Patients With Type 2 Diabetes After Hospital Discharge</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High blood glucose levels in hospitalized patients with diabetes are associated with&#xD;
      increased risk of medical complications and death. Improved glucose control with insulin&#xD;
      injections may improve clinical outcome and prevent some of the hospital complications.&#xD;
      Increasing evidence indicates that incretin-based agents are safe and effective for the&#xD;
      hospital management of patients with type 2 diabetes (T2D).&#xD;
&#xD;
      Liraglutide is a once-daily human glucagon-like peptide (GLP-1) analogue approved for the&#xD;
      treatment of T2D. Liraglutide has been shown to lower blood glucose, stimulate endogenous&#xD;
      insulin secretion, decrease plasma glucagon levels, inhibit gastric emptying, reduce food&#xD;
      intake and body weight and improve ß-cell function when administered subcutaneously.&#xD;
      Liraglutide increases insulin secretion in a glucose-dependent manner (i.e., only when plasma&#xD;
      glucose levels are elevated), resulting in low-risk of hypoglycemia when used as monotherapy.&#xD;
      When compared to insulin glargine therapy, the use of GLP-1 has resulted in comparable&#xD;
      reduction in HbA1c level, lower rates of hypoglycemia and less weight gain. No prospective&#xD;
      studies; however, have compared the efficacy and safety of liraglutide in the hospital&#xD;
      setting or after hospital discharge.&#xD;
&#xD;
      The primary objective is to compare the safety and efficacy of liraglutide (Victoza®) versus&#xD;
      glargine insulin in combination to oral anti-diabetic agents (OADs: metformin, sulfonylureas,&#xD;
      nateglinide, repaglinide or pioglitazone) on glycemic control after 26 weeks of treatment in&#xD;
      medicine patients with T2D after hospital discharge.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aim: To determine whether treatment with liraglutide (Victoza®) will result in&#xD;
      similar glycemic control (HbA1c at 26 weeks) and a lower rate of hypoglycemic events compared&#xD;
      to treatment with glargine (Lantus®) in patients with T2D after hospital discharge. Patients&#xD;
      with poorly controlled (HbA1c &gt;7%-10%) T2D treated with diet or oral antidiabetic agents or&#xD;
      low dose insulin naïve (0.4u/kg/day) prior to admission will be randomized to liraglutide or&#xD;
      glargine in combination to OADs at hospital discharge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Actual">August 30, 2020</completion_date>
  <primary_completion_date type="Actual">August 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic Control at Hospital Discharge and 6 Months Follow up</measure>
    <time_frame>Hospital discharge, 6 months (26 weeks)</time_frame>
    <description>To determine differences in HbA1c concentration at 26 weeks from discharge between liraglutide and glargine insulin therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting and Postprandial Blood Glucose (BG) Concentration After Follow up of 26 Weeks</measure>
    <time_frame>After discharge, average at 3 months (12 week) and 6 months (26 weeks)</time_frame>
    <description>To determine differences in BG concentration between liraglutide and glargine insulin therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic Episodes</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <description>Number of participants who had at least one hypoglycemic event (&lt;70 mg/dl) and severe hypoglycemic event (&lt;40 mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c &lt;7.0% and no Hypoglycemia</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <description>Percent of patients with 26 week HbA1c &lt;7.0% and no hypoglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c &lt;7.0% and no Weight Gain</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <description>Percent of patients with 26 week HbA1c &lt;7.0% and no weight gain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c &lt;7.0% and no Hypoglycemia</measure>
    <time_frame>After discharge, average 12 weeks</time_frame>
    <description>Percent of patients with 12 week HbA1c &lt;7.0% and no hypoglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight From Baseline</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <description>Change in body weight from baseline after 6 months of follow up (26 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BMI</measure>
    <time_frame>Baseline, and follow up after discharge (average 6 months)</time_frame>
    <description>Change in BMI after 6 months from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Dose of Insulin</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <description>Evaluate the total daily dose of insulin needed in the group receiving glargine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cardiovascular Risk Factors: Blood Pressure</measure>
    <time_frame>Baseline, 26 weeks post-intervention</time_frame>
    <description>Cardiovascular risk factors including changes in systolic and diastolic blood pressure from baseline to 26 weeks post-intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Risk Factor: Heart Rate</measure>
    <time_frame>26 weeks post-intervention</time_frame>
    <description>Cardiovascular risk: heart rate at baseline and 26 weeks post-intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Risk Factor: Lipid Profile</measure>
    <time_frame>26 weeks post-intervention</time_frame>
    <description>Lipid profile was measured with total cholesterol level results at 26 weeks post-intervention. This outcome was not part of standard of care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency Room Visits and Readmissions</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <description>Number of participants who had at least one emergency room visit and hospital readmissions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Renal Failure</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <description>Acute renal failure during the 26-week follow-up defined as a clinical diagnosis of acute renal failure with documented new-onset abnormal renal function (increment in creatinine &gt; 0.5 mg/dL from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-measured Blood Glucose (SMBG) 7-point Profiles at 26 Weeks Follow up</measure>
    <time_frame>26 weeks post-intervention</time_frame>
    <description>Number of participants that reported self-measured blood glucose (SMBG) 7-point profiles at 26 weeks follow up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">273</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Liraglutide + OADs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide once daily in combination to oral anti-diabetic agents (OADs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glargine + OADs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glargine once daily in combination to oral anti-diabetic agents (OADs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide + OADs</intervention_name>
    <description>Liraglutide subcutaneously daily</description>
    <arm_group_label>Liraglutide + OADs</arm_group_label>
    <other_name>Victoza® + OADs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glargine + OADs</intervention_name>
    <description>Glargine once daily subcutaneously</description>
    <arm_group_label>Glargine + OADs</arm_group_label>
    <other_name>Glargine (Lantus®) + OADs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females between the ages of 18 and 80 years discharged after hospital&#xD;
             admission from non- ICU general surgery and medicine services (excluding&#xD;
             gastrointestinal and cardiac surgeries).&#xD;
&#xD;
          2. Admission HbA1c between 7% and 10%&#xD;
&#xD;
          3. Patients with T2D treated with diet alone or with oral antidiabetic agents as&#xD;
             monotherapy or in combination therapy (excluding GLP1 receptor agonists) or on&#xD;
             low-dose insulin therapy (TDD ≤0.4 unit/kg/day) prior to admission.&#xD;
&#xD;
          4. Subjects with a hospital admission BG &lt; 400 mg/dL without laboratory evidence of&#xD;
             diabetic ketoacidosis (serum bicarbonate &lt; 18 mEq/L or positive serum or urinary&#xD;
             ketones).&#xD;
&#xD;
          5. BMI &gt; 25 Kg/m2 and ≤ 45 Kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt; 18 or &gt; 80 years.&#xD;
&#xD;
          2. Subjects with stress hyperglycemia (BG &gt; 140 mg/dL and HbA1c &lt; 6.5%)&#xD;
&#xD;
          3. Subjects with a history of type 1 diabetes&#xD;
&#xD;
          4. Treatment with insulin or GLP-1 analogs during the past 3 months prior to admission.&#xD;
&#xD;
          5. Recurrent severe hypoglycemia or hypoglycemic unawareness.&#xD;
&#xD;
          6. Subjects with gastrointestinal obstruction, gastroparesis, or those expected to&#xD;
             require gastrointestinal suction.&#xD;
&#xD;
          7. History of medullary thyroid cancer or multiple endocrine neoplasias&#xD;
&#xD;
          8. Patients with acute or chronic pancreatitis, pancreatic cancer, or gallbladder&#xD;
             disease.&#xD;
&#xD;
          9. Patients with clinically significant hepatic disease (cirrhosis, jaundice, end-stage&#xD;
             liver disease, portal hypertension) and elevated ALT and AST &gt; 3 times upper limit of&#xD;
             normal, or significantly impaired renal function (GFR &lt; 30 ml/min).&#xD;
&#xD;
         10. Treatment with oral or injectable corticosteroid (equivalent or higher than prednisone&#xD;
             5mg/day), parenteral nutrition, and immunosuppressive treatment.&#xD;
&#xD;
         11. Mental condition rendering the subject unable to understand the nature, scope, and&#xD;
             possible consequences of the study.&#xD;
&#xD;
         12. Female subjects who are pregnant or breastfeeding at the time of enrollment into the&#xD;
             study.&#xD;
&#xD;
         13. Females of childbearing potential who are not using adequate contraceptive methods (as&#xD;
             required by local law or practice).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo E Umpierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University SOM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Universtiy Hospital at MIdtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of NY at Buffalo</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 30, 2013</study_first_submitted>
  <study_first_submitted_qc>August 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2013</study_first_posted>
  <results_first_submitted>August 30, 2021</results_first_submitted>
  <results_first_submitted_qc>October 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 3, 2021</results_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Guillermo Umpierrez, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Incretins</keyword>
  <keyword>Liraglutide</keyword>
  <keyword>Glargine</keyword>
  <keyword>Randomized controlled trial</keyword>
  <keyword>basal insulin</keyword>
  <keyword>hospital discharge</keyword>
  <keyword>inpatient diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT01919489/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Liraglutide + OADs</title>
          <description>Liraglutide once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Liraglutide + OADs: Liraglutide subcutaneously daily</description>
        </group>
        <group group_id="P2">
          <title>Glargine + OADs</title>
          <description>Glargine once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Glargine + OADs: Glargine once daily subcutaneously</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Rejected the need of injections</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hospital readmission</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Liraglutide + OADs</title>
          <description>Liraglutide once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Liraglutide + OADs: Liraglutide subcutaneously daily</description>
        </group>
        <group group_id="B2">
          <title>Glargine + OADs</title>
          <description>Glargine once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Glargine + OADs: Glargine once daily subcutaneously</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="136"/>
            <count group_id="B2" value="137"/>
            <count group_id="B3" value="273"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.1" spread="9.5"/>
                    <measurement group_id="B2" value="55.9" spread="11.2"/>
                    <measurement group_id="B3" value="56.1" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glycemic Control at Hospital Discharge and 6 Months Follow up</title>
        <description>To determine differences in HbA1c concentration at 26 weeks from discharge between liraglutide and glargine insulin therapy</description>
        <time_frame>Hospital discharge, 6 months (26 weeks)</time_frame>
        <population>Number of subjects analyzed at 6 months differs from overall number of subjects analyzed, due to patients unable to complete the trial: 56 in the Liraglutide Arm and 44 in the Glargine Arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide + OADs</title>
            <description>Liraglutide once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Liraglutide + OADs: Liraglutide subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Glargine + OADs</title>
            <description>Glargine once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Glargine + OADs: Glargine once daily subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Glycemic Control at Hospital Discharge and 6 Months Follow up</title>
          <description>To determine differences in HbA1c concentration at 26 weeks from discharge between liraglutide and glargine insulin therapy</description>
          <population>Number of subjects analyzed at 6 months differs from overall number of subjects analyzed, due to patients unable to complete the trial: 56 in the Liraglutide Arm and 44 in the Glargine Arm.</population>
          <units>% (mmol/mol)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HbA1C at hospital discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="0.9"/>
                    <measurement group_id="O2" value="8.4" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1C at 6 months post-intervention</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.13" spread="1.3"/>
                    <measurement group_id="O2" value="7.68" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting and Postprandial Blood Glucose (BG) Concentration After Follow up of 26 Weeks</title>
        <description>To determine differences in BG concentration between liraglutide and glargine insulin therapy</description>
        <time_frame>After discharge, average at 3 months (12 week) and 6 months (26 weeks)</time_frame>
        <population>The number of subjects analyzed in this outcome at different time points from the overall number of subjects analyzed in other timepoints because it includes only those participants who were able to provide blood glucose results at the specified time points reported (12 and 26 weeks).</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide + OADs</title>
            <description>Liraglutide once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Liraglutide + OADs: Liraglutide subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Glargine + OADs</title>
            <description>Glargine once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Glargine + OADs: Glargine once daily subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting and Postprandial Blood Glucose (BG) Concentration After Follow up of 26 Weeks</title>
          <description>To determine differences in BG concentration between liraglutide and glargine insulin therapy</description>
          <population>The number of subjects analyzed in this outcome at different time points from the overall number of subjects analyzed in other timepoints because it includes only those participants who were able to provide blood glucose results at the specified time points reported (12 and 26 weeks).</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fasting blood glucose at 26 weeks follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.61" spread="2.2"/>
                    <measurement group_id="O2" value="8.56" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-prandial blood glucose at 12 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.67" spread="1.6"/>
                    <measurement group_id="O2" value="9.32" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postprandial blood glucose at 26 weeks follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.23" spread="2.8"/>
                    <measurement group_id="O2" value="8.72" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fasting blood glucose at 12 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.96" spread="3.3"/>
                    <measurement group_id="O2" value="7.70" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycemic Episodes</title>
        <description>Number of participants who had at least one hypoglycemic event (&lt;70 mg/dl) and severe hypoglycemic event (&lt;40 mg/dl)</description>
        <time_frame>After discharge, average 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide + OADs</title>
            <description>Liraglutide once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Liraglutide + OADs: Liraglutide subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Glargine + OADs</title>
            <description>Glargine once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Glargine + OADs: Glargine once daily subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemic Episodes</title>
          <description>Number of participants who had at least one hypoglycemic event (&lt;70 mg/dl) and severe hypoglycemic event (&lt;40 mg/dl)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants who had at least one hypoglycemic events (&lt;70 mg/dl)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants who had at least one severe hypoglycemic event (&lt;40 mg/dl)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c &lt;7.0% and no Hypoglycemia</title>
        <description>Percent of patients with 26 week HbA1c &lt;7.0% and no hypoglycemia</description>
        <time_frame>After discharge, average 6 months</time_frame>
        <population>This outcome included only participants with available data for both variables: HbA1c and hypoglycemia</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide + OADs</title>
            <description>Liraglutide once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Liraglutide + OADs: Liraglutide subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Glargine + OADs</title>
            <description>Glargine once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Glargine + OADs: Glargine once daily subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c &lt;7.0% and no Hypoglycemia</title>
          <description>Percent of patients with 26 week HbA1c &lt;7.0% and no hypoglycemia</description>
          <population>This outcome included only participants with available data for both variables: HbA1c and hypoglycemia</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c &lt;7.0% and no Weight Gain</title>
        <description>Percent of patients with 26 week HbA1c &lt;7.0% and no weight gain</description>
        <time_frame>After discharge, average 6 months</time_frame>
        <population>This outcome included only participants with available data for both variables: HbA1c and weight</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide + OADs</title>
            <description>Liraglutide once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Liraglutide + OADs: Liraglutide subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Glargine + OADs</title>
            <description>Glargine once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Glargine + OADs: Glargine once daily subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c &lt;7.0% and no Weight Gain</title>
          <description>Percent of patients with 26 week HbA1c &lt;7.0% and no weight gain</description>
          <population>This outcome included only participants with available data for both variables: HbA1c and weight</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c &lt;7.0% and no Hypoglycemia</title>
        <description>Percent of patients with 12 week HbA1c &lt;7.0% and no hypoglycemia</description>
        <time_frame>After discharge, average 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide + OADs</title>
            <description>Liraglutide once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Liraglutide + OADs: Liraglutide subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Glargine + OADs</title>
            <description>Glargine once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Glargine + OADs: Glargine once daily subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c &lt;7.0% and no Hypoglycemia</title>
          <description>Percent of patients with 12 week HbA1c &lt;7.0% and no hypoglycemia</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight From Baseline</title>
        <description>Change in body weight from baseline after 6 months of follow up (26 weeks)</description>
        <time_frame>After discharge, average 6 months</time_frame>
        <population>This outcome only included participants with available data for body weight in Kgs at baseline and 26 weeks follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide + OADs</title>
            <description>Liraglutide once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Liraglutide + OADs: Liraglutide subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Glargine + OADs</title>
            <description>Glargine once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Glargine + OADs: Glargine once daily subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight From Baseline</title>
          <description>Change in body weight from baseline after 6 months of follow up (26 weeks)</description>
          <population>This outcome only included participants with available data for body weight in Kgs at baseline and 26 weeks follow up.</population>
          <units>Kgs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline weight at discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.0" spread="20.6"/>
                    <measurement group_id="O2" value="98.2" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight at six months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2" spread="19.9"/>
                    <measurement group_id="O2" value="98.3" spread="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight change from baseline (discharge) to 6 months after discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.77" spread="8"/>
                    <measurement group_id="O2" value="0.6" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BMI</title>
        <description>Change in BMI after 6 months from baseline</description>
        <time_frame>Baseline, and follow up after discharge (average 6 months)</time_frame>
        <population>This outcome only included participants with available data for BMI at baseline and follow up of 26 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide + OADs</title>
            <description>Liraglutide once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Liraglutide + OADs: Liraglutide subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Glargine + OADs</title>
            <description>Glargine once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Glargine + OADs: Glargine once daily subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BMI</title>
          <description>Change in BMI after 6 months from baseline</description>
          <population>This outcome only included participants with available data for BMI at baseline and follow up of 26 weeks.</population>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline BMI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5" spread="5.3"/>
                    <measurement group_id="O2" value="33.3" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BMI at 26 weeks follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7" spread="6.8"/>
                    <measurement group_id="O2" value="33.3" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Dose of Insulin</title>
        <description>Evaluate the total daily dose of insulin needed in the group receiving glargine</description>
        <time_frame>After discharge, average 6 months</time_frame>
        <population>This outcome analyzed participants with available medication dose for the 26 weeks follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide + OADs</title>
            <description>Liraglutide once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Liraglutide + OADs: Liraglutide subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Glargine + OADs</title>
            <description>Glargine once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Glargine + OADs: Glargine once daily subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Dose of Insulin</title>
          <description>Evaluate the total daily dose of insulin needed in the group receiving glargine</description>
          <population>This outcome analyzed participants with available medication dose for the 26 weeks follow up.</population>
          <units>IU per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="20.9" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cardiovascular Risk Factors: Blood Pressure</title>
        <description>Cardiovascular risk factors including changes in systolic and diastolic blood pressure from baseline to 26 weeks post-intervention</description>
        <time_frame>Baseline, 26 weeks post-intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide + OADs</title>
            <description>Liraglutide once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Liraglutide + OADs: Liraglutide subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Glargine + OADs</title>
            <description>Glargine once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Glargine + OADs: Glargine once daily subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cardiovascular Risk Factors: Blood Pressure</title>
          <description>Cardiovascular risk factors including changes in systolic and diastolic blood pressure from baseline to 26 weeks post-intervention</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic blood pressure at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134" spread="17"/>
                    <measurement group_id="O2" value="130" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic blood pressure at 26 weeks follow up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136" spread="22"/>
                    <measurement group_id="O2" value="135" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" spread="11"/>
                    <measurement group_id="O2" value="77" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure at 26 weeks follow up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" spread="13"/>
                    <measurement group_id="O2" value="79" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiovascular Risk Factor: Heart Rate</title>
        <description>Cardiovascular risk: heart rate at baseline and 26 weeks post-intervention</description>
        <time_frame>26 weeks post-intervention</time_frame>
        <population>This outcome included patients with available heart rate data at 26 weeks follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide + OADs</title>
            <description>Liraglutide once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Liraglutide + OADs: Liraglutide subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Glargine + OADs</title>
            <description>Glargine once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Glargine + OADs: Glargine once daily subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiovascular Risk Factor: Heart Rate</title>
          <description>Cardiovascular risk: heart rate at baseline and 26 weeks post-intervention</description>
          <population>This outcome included patients with available heart rate data at 26 weeks follow-up.</population>
          <units>beats/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart rate at baseline (discharge)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" spread="14"/>
                    <measurement group_id="O2" value="79" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate at 6 months post-discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" spread="13"/>
                    <measurement group_id="O2" value="79" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiovascular Risk Factor: Lipid Profile</title>
        <description>Lipid profile was measured with total cholesterol level results at 26 weeks post-intervention. This outcome was not part of standard of care.</description>
        <time_frame>26 weeks post-intervention</time_frame>
        <population>Total cholesterol was measured in 9 subjects only due to limited funding.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide + OADs</title>
            <description>Liraglutide once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Liraglutide + OADs: Liraglutide subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Glargine + OADs</title>
            <description>Glargine once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Glargine + OADs: Glargine once daily subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiovascular Risk Factor: Lipid Profile</title>
          <description>Lipid profile was measured with total cholesterol level results at 26 weeks post-intervention. This outcome was not part of standard of care.</description>
          <population>Total cholesterol was measured in 9 subjects only due to limited funding.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190" spread="6"/>
                    <measurement group_id="O2" value="130" spread="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Emergency Room Visits and Readmissions</title>
        <description>Number of participants who had at least one emergency room visit and hospital readmissions</description>
        <time_frame>After discharge, average 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide + OADs</title>
            <description>Liraglutide once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Liraglutide + OADs: Liraglutide subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Glargine + OADs</title>
            <description>Glargine once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Glargine + OADs: Glargine once daily subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Emergency Room Visits and Readmissions</title>
          <description>Number of participants who had at least one emergency room visit and hospital readmissions</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with at least one ER visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with at least one hospital readmission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Renal Failure</title>
        <description>Acute renal failure during the 26-week follow-up defined as a clinical diagnosis of acute renal failure with documented new-onset abnormal renal function (increment in creatinine &gt; 0.5 mg/dL from baseline)</description>
        <time_frame>After discharge, average 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide + OADs</title>
            <description>Liraglutide once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Liraglutide + OADs: Liraglutide subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Glargine + OADs</title>
            <description>Glargine once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Glargine + OADs: Glargine once daily subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Renal Failure</title>
          <description>Acute renal failure during the 26-week follow-up defined as a clinical diagnosis of acute renal failure with documented new-onset abnormal renal function (increment in creatinine &gt; 0.5 mg/dL from baseline)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Self-measured Blood Glucose (SMBG) 7-point Profiles at 26 Weeks Follow up</title>
        <description>Number of participants that reported self-measured blood glucose (SMBG) 7-point profiles at 26 weeks follow up</description>
        <time_frame>26 weeks post-intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide + OADs</title>
            <description>Liraglutide once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Liraglutide + OADs: Liraglutide subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Glargine + OADs</title>
            <description>Glargine once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Glargine + OADs: Glargine once daily subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Self-measured Blood Glucose (SMBG) 7-point Profiles at 26 Weeks Follow up</title>
          <description>Number of participants that reported self-measured blood glucose (SMBG) 7-point profiles at 26 weeks follow up</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data collected during follow up (6 months post-intervention).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Liraglutide + OADs</title>
          <description>Liraglutide once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Liraglutide + OADs: Liraglutide subcutaneously daily</description>
        </group>
        <group group_id="E2">
          <title>Glargine + OADs</title>
          <description>Glargine once daily in combination to oral anti-diabetic agents (OADs)&#xD;
Glargine + OADs: Glargine once daily subcutaneously</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" events="21" subjects_affected="12" subjects_at_risk="136"/>
                <counts group_id="E2" events="34" subjects_affected="13" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="136"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Readmissions</sub_title>
                <counts group_id="E1" events="60" subjects_affected="35" subjects_at_risk="136"/>
                <counts group_id="E2" events="94" subjects_affected="43" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Medication discontinued due to AEs</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Francisco Pasquel</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-1695</phone>
      <email>fpasque@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

